Entry Into a Material Definitive Agreement. On October 23, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License Agreement (the “Agreement”) with Senju Pharmaceutical Co., Ltd. (“Senju”) to license a late-stage neuroprotective, oral small-molecule calpain inhibitor (“KIO-401”). Under the Agreement, which has an effective date of October 5, 2026, Senju granted the Company an exclusive, sublicensable license to develop, manufacture, commercialize, and otherwise exp…

Executive Vice President — Keith Lane: The company appointed an experienced external candidate as Executive Vice President, Head of Clinical Development and Regulatory Affairs, which is a significant addition to the management team rather than a departure.

Entry Into a Material Definitive Agreement. License Agreement Effective August 20, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Development Agreement (the “Agreement”) with Chong Jun Dang Pharmaceutical Corporation (“CKD”) with respect to the Company’s KIO-301 molecular photoswitch product (the “Product”). Under the Agreement, the Company granted to CKD an exclusive, sublicensable license to develop, manufacture, commercialize, and file for regulator…

Results of Operations and Financial Conditions. On May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that s…

The filing details an equity plan amendment and is not related to any management changes.

Results of Operations and Financial Conditions. On May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that s…

The Private Placement Shares, the Tranche A-1 Warrants, the Tranche A-2 Warrants, the Pre-Funded Warrants, and the shares of common stock underlying the Tranche A-1 Warrants, the Tranche A-2 Warrants and the Pre-Funded Warrants (collectively, the “Securities”) were, and will be, offered and sold in transactions exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder. Each Purchaser is an “accredited investor,” as defi…

Entry Into a Material Definitive Agreement. Private Placement On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 438,471 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per s…

Chief Development Officer — Eric J. Daniels, M.D., MBA: Resigned to pursue another opportunity.

Results of Operations and Financial Conditions. On March 25, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of tha…

Results of Operations and Financial Conditions. On November 7, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability…

Results of Operations and Financial Conditions. On August 8, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that…

Entry Into a Material Definitive Agreement. License Agreement On May 30, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive Option Agreement (the “Agreement”) with Senju Pharmaceutical Co., Ltd. (“Senju”) with respect to the Company’s KIO-301 molecular photoswitch product (the “Product”). Under the Agreement, the Company granted to Senju an exclusive option to exercise rights to an exclusive development and commercialization agreement to the Product throughout certain…

Results of Operations and Financial Conditions. On May 9, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that s…

Results of Operations and Financial Conditions. On March 25, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of tha…

Results of Operations and Financial Conditions. On November 8, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability…

Results of Operations and Financial Conditions. On August 9, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that…

Material Modification to Rights of Security Holders. The information set forth in

Results of Operations and Financial Conditions. On May 10, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that…

Results of Operations and Financial Conditions. On March 25, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of tha…

Entry Into a Material Definitive Agreement. Private Placement On January 31, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 15,800,000 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01…

The Private Placement Shares, the Tranche A Warrants, the Tranche B Warrants, the Pre-Funded Warrants, and the shares of common stock underlying the Tranche A Warrants, the Tranche B Warrants and the Pre-Funded Warrants (collectively, the “Securities”) were, and will be, offered and sold in transactions exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder. Each Purchaser is an “accredited investor,” as defined in R…

Entry Into a Material Definitive Agreement. License Agreement On January 25, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Development Agreement (the “Agreement”) with Théa Open Innovation SAS (“TOI”) with respect to the Company’s KIO-301 molecular photoswitch product (the “Product”). Under the Agreement, the Company granted to TOI an exclusive, sublicensable license to develop, manufacture, commercialize, and file for regulatory approvals with respec…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on July 18, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the min…

Results of Operations and Financial Conditions. On November 9, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended September 30, 2023 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liab…